A cultural gap exists where many European academics focus on immediate research rather than engaging with the investment community. This contrasts with the US, where entrepreneurialism is more ingrained, leading to more successful academia-to-industry transitions.
Leiden Labs, a Dutch company founded by industry veterans, failed to raise capital from local investors but secured $30 million from US VCs, including Google Ventures, within a week. This illustrates the faster pace and higher risk appetite of the US venture ecosystem for European biotech.
A common pitfall for academic founders is surrounding themselves with subpar business talent. While meticulous about scientific collaborators, they are less rigorous when selecting business partners and early investors, leading to irreversible mistakes that hinder long-term success.
Instead of focusing on traditional disease indications, researchers are exploring fundamental mechanisms like the scar-free tissue remodeling in the endometrium or sleep's role in neurodegeneration. These processes act as a 'lens' for discovering therapies with broad applications across many diseases.
Drug developers can now combine multiple specificities into hyper-complex molecules. However, there's concern that this engineering-first approach, without a strong biological hypothesis, creates constructs too complex to predict in vivo, risking a return to less-targeted screening methods.
A key overlooked parameter in building autonomous labs is 'knowledge'—not just scientific data, but the practical expertise of technicians in handling failures. Without embedding this troubleshooting logic into the system, labs cannot achieve true 24/7 autonomy and will fail to scale cost-effectively.
The negative trial result for Novartis's Lp(a) cardiovascular drug is a landmark event prompting re-evaluation of the industry's heavy reliance on human genetic data for target validation. It questions if targeting a lifelong genetic risk factor is effective once a disease is established.